Member Info for BuenaVista

I'm expecting a broad summary of the findings. Tables and graphs will come later during the Science Day and later still in published literature. Am I right in thinking that Avacta has as yet published no peer reviewed details of AVA6000 in the literature? And only that conference poster? Preclinical data will have been reviewed by MHRA and FDA of course, but none of that gets published.

Three beaming clues in the article that it's not AVA6000.

Doesn't matter, it's precision medicine, not us.
Good news though for Mr Glynn and gives hope to others.

What is the point of testing on arrival for doing contact tracing? With any positives, might as well put everyone on every plane into quarantine!

"Ever-expanding" ?
"Existing products" ?
Please explain. You seem to know more than anyone else does.

HurstBot can't cut the NY talk without the upgrade.

Having scanned the newly published patent literature and attended presentations by wannabe licensors, I can tell you that the pharma industry will be right on top of what's been published by and about Avacta IF THEY THINK it's going to be a competitor or an opportunity. Sure, Avacta's tech won't be the only thing being followed and it'll be a toss-up for each pharma company whether they ask Avacta to give a presentation or Avacts offers them a presentation, but presentations will have been taking place. How do you think pharma companies get a good handle on what the tech really is and what it really does (and what the issues and potential problems are)? Do you think they rely purely on published, public domain information? Would you, if there was a potential competitor/opportunity, just rely on what Avacta says with all the "only released in the TME" (despite the patent protection saying different), etc generalisations? Wouldn't you want to interrogate the people fully before signing up for or rejecting the opportunity? I've seen Paul, now Lord, Drayson sent away with a flea in his ear after presenting his PowerJect technology. Not saying that would happen with Avacta - I absolutely don't think it would - just that that's how it works. Who uses that PowderJect technology nowadays for insulin delivery?

And fyi PL75, any pharma company involved in oncology will of course be following Avacta and every other small company doing cancer research. Easiest way is patent publications and, in person, conference/seminar presentations, as well as the oncology journals. Why do you not think they wouldn't keep tabs on potential competition?

Pretty sure Avacta will be hawking their pipeline around the various pharma companies, giving personal on-site presentations (no market-sensitive info though) to each company's oncology and marketing experts and looking for NDAs followed by licensing agreements.

Just had a read through of TK's commetns. What an absolute moron. Shut up about what you know nothing about. Or do some reading so you don't come across as a complete pillock.

My guess is that all was just about finalised - data, biopsies, agreed indications for Phase 1b at agreed start time at agreed hospitals - and mostly written up release-ready by mid-December so that the RNS could be put out on the 19th.

My reasoning? If that wasn't the case Alan would have been better to say "early next year".

Besides, there will be a whole slew of development, milestone and licensing news betwix RNS and Science Day. Won't there?

Boring banner

Come on OP, man up and answer. If you have one.

Where did his wealth come from?

RNS lodged! ;O)

DEATH SPIRAL SAVIOUR!

Jounce to receive a total of $192m, then and now, rather than a prospective total of $770 for experimental cancer therapy, GS-1811. Atrocious market conditions for biotech companies cited.

-----------------------------------

Wed, December 28, 2022 at 2:34 AM GMT

(Reuters) - Gilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics for $67 million, the drugmaker said on Tuesday.

The amended licensing deal will bolster Jounce's cash resources in a challenging market for biotech companies.

Shares of Jounce more than doubled to $1.68, while Gilead's shares fell marginally in after market trading.

Gilead will now be solely responsible for all further development and commercialization of GS-1811 globally. The amended deal is expected to reduce its 2022 earnings per share by 4 cents on both GAAP and non-GAAP basis.

GS-1811 is currently being evaluated in an early-stage trial for patients with solid tumors and works by selectively depleting T-cells that suppress the body's immune response and allow tumors to grow.

In 2020, the drugmakers had agreed to collaborate on development of GS-1811, when Gilead made an upfront payment of $85 million to Jounce. Under the initial terms, Jounce was eligible to get up to $685 million in milestone payments from Gilead, of which it has received $40 million so far.

With the amendment, Jounce will no longer receive the remaining milestone payments or any of the sales-based royalties for the therapy.

Check out the posting history guys.

Claims to have bought low and sold high, then back in again around the 50s. I've no reason to disbelief this.

Just don't understand the comment about "AVACTA competitors are making much quicker gains in their treatment research". Surely if you've been following your investment, you'll know precisely what's been happening with AVA6000 and why we're where we are? Or do you just not understand the pharmaceutical R&D process?

Looks like waggy's office is open over the Christmas-New Year period. Not exactly the A Team!

AS seems to have a nose for disruptive or game-changing tech. This is the direction I'd like to see Avacta move - incubator and early-stage developer of new tech for pharma that can be taken to market by others, either the acquired original inventor company or licensed out.

AS is Chair of SPARTA Biodiscovery.
https://www.imperial.ac.uk/news/239811/new-startup-help-pharmaceutical-companies-develop/amp/

What have you been buying recently Seg? :)